Pharming’s wholly-owned subsidiary DNage has initiated an observational study in children suffering from Cockayne Syndrome (CS). The study is designed to assess the natural (untreated) progression of the
Sanaria has received grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a phase II Small
Cell Therapeutics (CTI) has released updated on 18-month follow-up clinical data for phase III EXTEND (PIX 301) trial of pixantrone (BBR2778) for patients with advanced, relapsed or refractory,
Progenics Pharmaceuticals has announced the promotion of Mark Baker to the newly created position of president. Mr Baker was also appointed to the Board of Directors. He will
Mylan has reported that its Indian subsidiary, Matrix Laboratories has received tentative approval from the FDA under the President’s Emergency Plan for AIDS Relief (PEPFAR) for its New
Avaxia Biologics has been awarded a phase I SBIR grant from the National Institute of Dental and Craniofacial Research to support the development of a novel antibody therapeutic
PharmAbcine has closed $6m in a Series A financing. OrbiMed’s Caduceus Asia Partners and Novartis Korea Venture Fund co-led the round, with additional participation from an international syndicate
The FDA has indicated that CEL-SCI can proceed with its first clinical trial to evaluate the effect of its investigational LEAPS-H1N1 treatment on the white blood cells of
Amgen has licensed the exclusive right to use ImmunoGen’s maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target found on solid tumors. Reportedly,
Hemispherx Biopharma’s (Hemispherx) board of directors has approved up to $4.4m for full engineering studies, capital improvements, system upgrades, and introduction of building management systems to enhance production
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.